Trials / Terminated
TerminatedNCT05788926
A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)
A Phase I Dose-escalation Trial of TG6050 Administered by Intravenous Infusion in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Transgene · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I, open-label, dose-escalation trial of TG6050 administered by single or repeated IV infusion(s).
Detailed description
This clinical trial aims at determining the dose and schedule of administration of TG6050 for further development, primarly based on the assessment of the safety and tolerability of single and repeated IV infusions at escalating doses in patients with advanced NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG6050 | Oncolytic Vaccinia virus containing genes encoding the human interleukin 12 (IL-12) and an anti-CTLA4 antibody administered at different dose. |
Timeline
- Start date
- 2023-04-05
- Primary completion
- 2025-06-23
- Completion
- 2025-06-23
- First posted
- 2023-03-29
- Last updated
- 2025-07-09
Locations
5 sites across 1 country: France
Source: ClinicalTrials.gov record NCT05788926. Inclusion in this directory is not an endorsement.